Table 1—

Demographic and clinical characteristics of the study participants at baseline ITT population

Placebo + lifestyleOrlistat + lifestyle
n1,6371,640
Sex (n [%])
 Female905 (55.3)905 (55.2)
 Male732 (44.7)735 (44.8)
Age (years)43.7 ± 8.043.0 ± 8.0
Weight (kg)110.6 ± 16.5110.4 ± 16.3
BMI (kg/m2)37.4 ± 4.537.3 ± 4.2
Waist circumference (cm)115.4 ± 10.4115.0 ± 10.4
IGT patients (n [%])344 (21)350 (21.3)
Whole blood glucose
 Fasting (mmol/l)4.6 ± 0.64.6 ± 0.6
 2 h (mmol/l)5.5 ± 1.65.5 ± 1.6
 AUC (mmol · min−1 · l−1)799 ± 179804 ± 175
Serum insulin
 Fasting (pmol/l)83.6 ± 47.286.1 ± 50.1
 2 h (pmol/l)344.9 ± 298.5370.9 ± 336.7
 AUC (nmol · min−1 · l−1)47.7 ± 28.449.7 ± 31.3
Diastolic BP (mmHg)82.3 ± 10.082.0 ± 10.0
Systolic BP (mmHg)130.4 ± 15.4130.8 ± 15.8
Total cholesterol (mmol/l)5.8 ± 1.05.8 ± 1.0
LDL cholesterol (mmol/l)3.8 ± 0.93.7 ± 0.9
HDL cholesterol (mmol/l)1.2 ± 0.31.2 ± 0.3
LDL-to-HDL ratio3.3 ± 1.03.2 ± 1.1
Triglycerides (mmol/l)1.9 ± 1.21.9 ± 1.0
Fibrinogen (μmol/l)11.7 ± 2.011.7 ± 2.2
Plasminogen activator inhibitor-1 (U/ml)22.9 ± 10.023.1 ± 10.0
Energy intake (kcal/day)2,927 ± 1,1482,909 ± 1,030
  • Data are means ± SD, unless otherwise noted. AUC, area under the curve, BP, blood pressure.